Humana Inc. Raises FY 2025 Adjusted EPS Guidance to $17.00, Reports 2Q25 GAAP EPS of $4.51 and Adjusted EPS of $6.27, Increases Revenue Guidance to At Least $128 Billion

Reuters
07/30
Humana Inc. Raises FY 2025 Adjusted EPS Guidance to $17.00, Reports 2Q25 GAAP EPS of $4.51 and Adjusted EPS of $6.27, Increases Revenue Guidance to At Least $128 Billion

Humana Inc. reported its financial results for the second quarter of 2025, showcasing significant performance metrics and updates. The company announced earnings per share $(EPS)$ of $4.51 on a GAAP basis, with an adjusted EPS of $6.27 for the quarter. Year-to-date EPS stood at $14.81 on a GAAP basis and $17.85 on an adjusted basis. The insurance segment benefit ratio was reported at 89.9%, aligning with the company's previous expectation of approximately 90%. Humana revised its full-year 2025 GAAP EPS guidance to approximately $13.77, down from the prior estimate of approximately $14.68. However, it raised its adjusted FY 2025 EPS guidance to approximately $17.00, from the previous guidance of approximately $16.25. In terms of revenue, Humana increased its full-year 2025 consolidated revenue guidance to at least $128 billion, up from the previous range of $126 billion to $128 billion. The company also affirmed its FY 2025 insurance segment benefit ratio guidance range of 90.1% to 90.5%. Humana highlighted the strategic focus on investing in improved outcomes, operational excellence, and enhancing customer and investor experiences.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humana Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250730069182) on July 30, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10